Microbix Biosystems (MBX.TO) Stock Price

Microbix Biosystems Price

TSX·CLOSED
0.30CAD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 9.0% per year over the past 19 years to 18.59 M CAD. Earnings per share have grown at 91.3% per year over the last 11 years. Microbix Biosystems's net margin stands at -12.1%, down from 8.8% several years earlier. Analysts set a median price target of 0.51 CAD, implying 70.0% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 43% above its 52-week low.

Microbix Biosystems stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Microbix Biosystems over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Microbix Biosystems stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Microbix Biosystems's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Microbix Biosystems Stock Price History
DateMicrobix Biosystems Price
7/31/20260.30 CAD
7/30/20260.30 CAD
7/29/20260.31 CAD
7/27/20260.31 CAD
7/23/20260.30 CAD
7/22/20260.31 CAD
7/21/20260.31 CAD
7/20/20260.30 CAD
7/17/20260.30 CAD
7/16/20260.30 CAD
7/15/20260.30 CAD
7/14/20260.31 CAD
7/13/20260.31 CAD
7/10/20260.32 CAD
7/9/20260.30 CAD
7/8/20260.31 CAD
7/7/20260.31 CAD
7/6/20260.30 CAD
7/3/20260.30 CAD
7/2/20260.30 CAD
6/30/20260.30 CAD
6/29/20260.29 CAD
6/26/20260.30 CAD
6/25/20260.31 CAD
6/24/20260.29 CAD
6/23/20260.29 CAD
6/22/20260.30 CAD
6/19/20260.31 CAD
6/18/20260.30 CAD
6/17/20260.31 CAD
6/16/20260.29 CAD
6/15/20260.29 CAD
6/12/20260.30 CAD
6/11/20260.29 CAD
6/10/20260.29 CAD
6/9/20260.28 CAD
6/8/20260.27 CAD
6/5/20260.27 CAD
6/4/20260.27 CAD
6/3/20260.27 CAD
6/2/20260.27 CAD
6/1/20260.27 CAD
5/29/20260.27 CAD
5/28/20260.28 CAD
5/27/20260.28 CAD
5/26/20260.27 CAD
5/25/20260.26 CAD
5/22/20260.25 CAD
5/21/20260.24 CAD
5/20/20260.23 CAD
5/19/20260.23 CAD
5/15/20260.23 CAD
5/14/20260.23 CAD
5/13/20260.26 CAD
5/12/20260.27 CAD
5/11/20260.25 CAD
5/8/20260.25 CAD
5/7/20260.25 CAD
5/6/20260.25 CAD
5/5/20260.25 CAD
5/4/20260.26 CAD
5/1/20260.26 CAD
4/30/20260.26 CAD
4/29/20260.25 CAD
4/28/20260.25 CAD
4/27/20260.26 CAD
4/24/20260.25 CAD
4/23/20260.25 CAD
4/22/20260.25 CAD
4/21/20260.25 CAD
4/20/20260.24 CAD
4/17/20260.24 CAD
4/16/20260.24 CAD
4/15/20260.25 CAD
4/14/20260.25 CAD
4/13/20260.24 CAD
4/10/20260.24 CAD
4/9/20260.24 CAD
4/8/20260.24 CAD
4/7/20260.23 CAD
4/6/20260.25 CAD
4/2/20260.23 CAD
3/27/20260.23 CAD
3/26/20260.24 CAD
3/25/20260.24 CAD
3/24/20260.23 CAD
3/23/20260.24 CAD
3/20/20260.25 CAD
3/19/20260.25 CAD
3/18/20260.25 CAD
3/17/20260.25 CAD
3/16/20260.25 CAD
3/13/20260.24 CAD
3/12/20260.25 CAD
3/11/20260.26 CAD
3/10/20260.26 CAD
3/9/20260.23 CAD
3/6/20260.23 CAD
3/5/20260.23 CAD
3/4/20260.24 CAD
2/26/20260.24 CAD
2/25/20260.24 CAD
2/24/20260.24 CAD
2/23/20260.24 CAD
2/20/20260.23 CAD
2/19/20260.24 CAD
2/18/20260.24 CAD
2/16/20260.23 CAD
2/12/20260.22 CAD
2/11/20260.23 CAD
2/10/20260.23 CAD
2/9/20260.23 CAD
2/8/20260.22 CAD
2/5/20260.23 CAD
2/4/20260.24 CAD
2/3/20260.23 CAD
2/2/20260.22 CAD
2/1/20260.22 CAD
1/29/20260.22 CAD
1/28/20260.23 CAD
1/27/20260.23 CAD
1/26/20260.22 CAD
1/25/20260.22 CAD
1/22/20260.22 CAD
1/21/20260.22 CAD
1/20/20260.22 CAD
1/19/20260.22 CAD
1/18/20260.23 CAD
1/15/20260.24 CAD
1/14/20260.24 CAD
1/13/20260.24 CAD
1/12/20260.24 CAD
1/11/20260.24 CAD
1/8/20260.25 CAD
1/7/20260.24 CAD
1/6/20260.24 CAD
1/5/20260.25 CAD
1/4/20260.24 CAD
1/1/20260.24 CAD
12/30/20250.23 CAD
12/29/20250.24 CAD
12/28/20250.24 CAD
12/23/20250.23 CAD
12/22/20250.23 CAD
12/21/20250.23 CAD
12/18/20250.22 CAD
12/17/20250.21 CAD
12/16/20250.24 CAD
12/15/20250.24 CAD
12/14/20250.24 CAD
12/11/20250.25 CAD
12/10/20250.25 CAD
12/9/20250.24 CAD
12/8/20250.24 CAD
12/7/20250.25 CAD
12/4/20250.24 CAD
12/3/20250.24 CAD
12/2/20250.24 CAD
12/1/20250.24 CAD
11/30/20250.24 CAD
11/27/20250.25 CAD
11/26/20250.25 CAD
11/25/20250.24 CAD
11/24/20250.25 CAD
11/23/20250.24 CAD
11/20/20250.25 CAD
11/19/20250.24 CAD
11/18/20250.24 CAD
11/17/20250.24 CAD
11/16/20250.25 CAD
11/13/20250.25 CAD
11/12/20250.27 CAD
11/11/20250.26 CAD
11/10/20250.25 CAD
11/9/20250.25 CAD
11/6/20250.25 CAD
11/5/20250.25 CAD
11/4/20250.25 CAD
11/3/20250.26 CAD
11/2/20250.25 CAD
10/30/20250.25 CAD
10/29/20250.25 CAD
10/28/20250.25 CAD
10/27/20250.25 CAD
10/26/20250.26 CAD
10/23/20250.25 CAD
10/22/20250.26 CAD
10/21/20250.25 CAD
10/20/20250.25 CAD
10/19/20250.24 CAD
10/16/20250.26 CAD
10/15/20250.26 CAD
10/14/20250.26 CAD
10/13/20250.27 CAD
10/9/20250.27 CAD
10/8/20250.27 CAD
10/7/20250.25 CAD
10/6/20250.26 CAD
10/5/20250.27 CAD
10/2/20250.26 CAD
10/1/20250.25 CAD
9/30/20250.26 CAD
9/29/20250.27 CAD
9/28/20250.26 CAD
9/25/20250.26 CAD
9/24/20250.27 CAD
9/23/20250.28 CAD
9/22/20250.27 CAD
9/21/20250.27 CAD
9/18/20250.25 CAD
9/17/20250.25 CAD
9/16/20250.24 CAD
9/15/20250.23 CAD
9/14/20250.24 CAD
9/11/20250.24 CAD
9/10/20250.23 CAD
9/9/20250.23 CAD
9/8/20250.24 CAD
9/7/20250.23 CAD
9/4/20250.24 CAD
9/3/20250.23 CAD
9/2/20250.25 CAD
9/1/20250.23 CAD
8/28/20250.24 CAD
8/27/20250.24 CAD
8/26/20250.24 CAD
8/25/20250.24 CAD
8/24/20250.24 CAD
8/21/20250.23 CAD
8/20/20250.24 CAD
8/19/20250.24 CAD
8/18/20250.24 CAD
8/17/20250.25 CAD
8/14/20250.25 CAD
8/13/20250.25 CAD
8/12/20250.28 CAD
8/11/20250.29 CAD
8/10/20250.29 CAD
8/7/20250.29 CAD
8/6/20250.29 CAD
8/5/20250.29 CAD
Access this data via the Eulerpool API
Get Free API Key

Microbix Biosystems Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
18.59 M CAD
4.84 M CAD
1.63 M CAD
Jan 1, 2022
19.08 M CAD
2.69 M CAD
1.79 M CAD
Jan 1, 2023
16.51 M CAD
799,895.00 CAD
-39,483.00 CAD
Jan 1, 2024
25.39 M CAD
3.91 M CAD
3.52 M CAD
Jan 1, 2025
18.59 M CAD
-1.71 M CAD
-2.25 M CAD
Jan 1, 2026 (e)
18.30 M CAD
2.04 M CAD
-1.39 M CAD
Jan 1, 2027 (e)
20.50 M CAD
2.29 M CAD
1.39 M CAD
Jan 1, 2028 (e)
24.60 M CAD
2.74 M CAD
0.00 CAD

Microbix Biosystems Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 4:07 PM
 
REVENUEM CAD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CAD
EBITM CAD
EBIT MARGIN%
NET INCOMEM CAD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
7.008.008.009.0010.0012.0013.0010.0018.0019.0016.0025.0018.0018.0020.0024.00
16.6714.29–12.5011.1120.008.33-23.0880.005.56-15.7956.25-28.00–11.1120.00
42.8650.0062.5044.4440.0041.6746.1540.0061.1157.8943.7560.0050.0050.0050.0050.00
3.004.005.004.004.005.006.004.0011.0011.007.0015.009.009.0010.0012.00
––––-3.00-7.001.00–4.002.00–3.00-1.002.002.002.00
––––-30.00-58.337.69–22.2210.53–12.00-5.5611.1110.008.33
––––-3.00-8.00–-6.001.001.00–3.00-2.00-1.001.00–
–––––166.67––-116.67–––-166.67-50.00-200.00–
66.6887.6884.7084.7096.7796.9796.97109.00146.77138.71137.59135.55139.05139.05139.05139.05
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Microbix Biosystems generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Microbix Biosystems retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Microbix Biosystems's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Microbix Biosystems has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Microbix Biosystems's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Microbix Biosystems stock margins

The Microbix Biosystems margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Microbix Biosystems. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Microbix Biosystems.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
59.40 %
26.01 %
8.77 %
Jan 1, 2022
58.32 %
14.11 %
9.38 %
Jan 1, 2023
45.30 %
4.84 %
-0.24 %
Jan 1, 2024
60.61 %
15.38 %
13.86 %
Jan 1, 2025
53.02 %
-9.18 %
-12.08 %
Jan 1, 2026 (e)
53.02 %
11.16 %
-7.60 %
Jan 1, 2027 (e)
53.02 %
11.16 %
6.79 %
Jan 1, 2028 (e)
53.02 %
11.16 %
0.00 %

Microbix Biosystems Stock Revenue, EBIT, Earnings per Share

The Microbix Biosystems earnings per share therefore indicates how much revenue Microbix Biosystems has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.13 CAD
0.03 CAD
0.01 CAD
Jan 1, 2022
0.14 CAD
0.02 CAD
0.01 CAD
Jan 1, 2023
0.12 CAD
0.01 CAD
-0.00 CAD
Jan 1, 2024
0.19 CAD
0.03 CAD
0.03 CAD
Jan 1, 2025
0.13 CAD
-0.01 CAD
-0.02 CAD
Jan 1, 2026 (e)
0.13 CAD
0.01 CAD
-0.01 CAD
Jan 1, 2027 (e)
0.15 CAD
0.02 CAD
0.01 CAD
Jan 1, 2028 (e)
0.18 CAD
0.02 CAD
0.00 CAD

Microbix Biosystems business model & stock analysis

Microbix Biosystems Inc. is a Canadian company specializing in the development and marketing of biological products and solutions in various industries. The company was founded in 1988 and is headquartered in Toronto, Ontario.

Microbix Biosystems SWOT Analysis

Strengths

Microbix Biosystems Inc boasts a strong portfolio of proprietary technologies and intellectual property, including its viral antigen production capabilities.

The company has established itself as a leader in the development and manufacture of critical biological products used in diagnostics, quality control, and research.

Microbix has a diverse range of end markets and customers, reducing dependency on any single sector or client.

Weaknesses

The company heavily relies on key customers for a significant portion of its revenue, which may present business continuity risks in case of customer departure.

Microbix faces competition from both established players and emerging companies in the biotherapeutics and diagnostics markets.

Limited financial resources may hamper the company's ability to invest in research and development and expand its operations.

Opportunities

The increasing demand for biopharmaceutical products and diagnostic solutions presents significant growth opportunities for Microbix Biosystems Inc.

Expanding into new geographic markets and strategic partnerships with leading industry players can help the company to strengthen its market position.

Leveraging its expertise in viral antigen production, Microbix can explore opportunities in vaccine development, particularly amid the current global health concerns.

Threats

Rapidly changing market dynamics and regulatory requirements could impact the company's ability to adapt and stay competitive.

Economic downturns or global crises may lead to reduced demand for the company's products and services.

The entry of new competitors with disruptive technologies and lower cost structures poses a threat to Microbix's market share and profitability.

Microbix Biosystems Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Microbix Biosystems historical P/E ratio, EBIT multiple, and P/S ratio

Microbix Biosystems annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Microbix Biosystems shares outstanding

The number of shares of Microbix Biosystems was 139.05 M in 2025. This indicates how many shares Microbix Biosystems is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
146.77 M Stocks
Jan 1, 2022
138.71 M Stocks
Jan 1, 2023
137.59 M Stocks
Jan 1, 2024
135.55 M Stocks
Jan 1, 2025
139.05 M Stocks
Jan 1, 2026 (e)
139.05 M Stocks
Jan 1, 2027 (e)
139.05 M Stocks
Jan 1, 2028 (e)
139.05 M Stocks

Current Microbix Biosystems forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
0.51
Last Price
0.29
Currency
CAD
12M Return Potential
75.86 %
LTM Return
0 %

Microbix Biosystems Earnings Calls

2025

Microbix Biosystems Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/9/20230.01CAD-5.99 MCAD-2023 Q3
5/10/20230.01CAD-5.99 MCAD-2023 Q2
2/8/20230.01CAD-5.89 MCAD-2023 Q1
12/21/20220.00CAD-5.33 MCAD-2022 Q4
8/11/20220.01CAD-5.47 MCAD-2022 Q3
5/12/20220.01CAD-6.01 MCAD-2022 Q2
2/10/20220.01CAD-5.07 MCAD-2022 Q1
12/23/20210.01CAD-6.29 MCAD-2021 Q4
8/12/20210.01CAD-6.09 MCAD-2021 Q3
5/13/2021-CAD-3.85 MCAD-2021 Q2

Microbix Biosystems shareholder structure

% Name
0.15479%
Microbix Biosystems Inc.
Microbix Biosystems Inc.

Microbix Biosystems Beneficial Ownership Filings (SEC 13D/G)

Free Float
83.6%
Float Shares
-
Shares Outstanding
-

Microbix Biosystems Executives and Management Board

7 members · avg. age 67 · 14 % women

CG

Mr. Cameron Groome

President, Chief Executive Officer and Director · since 2012

660,142.00 CAD

VE

Mr. Vaughn Embro-pantalony (67)

Independent Director · since 2007

221,516.00 CAD
MC

Dr. Mark Cochran

Independent Director

165,000.00 CAD
MM

Mr. Martin Marino

Independent Chairman of the Board

–
PB

Dr. Peter Blecher

Independent Director

–
JR

Mr. Joseph Renner

Independent Director

–
JS

Ms. Jennifer Stewart

Independent Director

–

Frequently asked questions about Microbix Biosystems

Microbix Biosystems Inc is a leading biotechnology company with a robust business model focused on developing and commercializing innovative biological products. The company specializes in producing and marketing unique biological substances, such as antigens and quality assessment controls, for diagnostic testing and scientific research. Microbix Biosystems Inc leverages its extensive expertise in virology, immunology, and bioprocessing to provide high-quality products to diagnostic laboratories, biopharmaceutical companies, and research institutions worldwide. With a continued commitment to advancing healthcare and scientific research, Microbix Biosystems Inc has established a strong reputation as a trusted partner in the industry.

Microbix Biosystems Inc is primarily active in the fields of virology and molecular diagnostics.

The main competitors of Microbix Biosystems Inc in the market include companies such as Becton, Dickinson and Company (BD), Bio-Rad Laboratories, and Meridian Bioscience Inc.

Microbix Biosystems Inc is a well-established company with a rich history and background. Founded in 1988, Microbix has grown to become a leading provider of biological products and technologies worldwide. The company specializes in the development, manufacture, and distribution of biological materials used in the diagnostics, research, and quality control fields. With its state-of-the-art facilities and dedicated team of experts, Microbix has consistently delivered innovative solutions to the global life sciences industry. Their wide range of products and services includes viral antigens, quality assessment programs, and proficiency panels. Throughout its history, Microbix Biosystems Inc has remained committed to providing high-quality products and contributing to advancements in the healthcare sector.

Microbix Biosystems Inc, a leading life science company, has accomplished several significant milestones. Notably, the company successfully developed and launched key products in the virology industry, including Quality Assessment (QA) controls for viral diseases and viral antigens. Microbix Biosystems Inc also introduced innovative technologies like the Kinlytic Urokinase, a clot-dissolving agent. Through strategic partnerships, the company expanded its global presence and garnered recognition for its exceptional research and development capabilities. Furthermore, Microbix Biosystems Inc achieved ISO 13485 certification, validating its commitment to quality management systems. These achievements solidify the company's position as a prominent player in the biotechnology sector.

Microbix Biosystems Inc is primarily present in Canada, United States, Europe, and Asia.

Microbix Biosystems Inc represents the values of exceptional innovation, dedication to quality, and commitment to customer satisfaction. As a leading biotechnology company, Microbix is driven by a strong corporate philosophy centered on advancing human health through the development and production of high-quality diagnostic reagents and viral antigens. With a focus on continuous improvement, Microbix strives to deliver superior products and services to meet the evolving needs of the healthcare industry. By prioritizing research and development, along with stringent quality control measures, Microbix Biosystems Inc ensures its reputation as a trusted provider of essential biological products.

Analysts currently set an average price target of 0.51 CAD for the Microbix Biosystems stock (median: 0.51 CAD), implying +75.9 % versus the latest price. The consensus is based on 5 analyst ratings.

Microbix Biosystems Analyst Price Targets 2026

5 analysts currently rate the Microbix Biosystems stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Microbix Biosystems to generate revenue of 18.30 M CAD and earnings per share of -0.01 CAD.

Microbix Biosystems Analyst Price Targets 2026

Converted at the current exchange rate, the Microbix Biosystems share trades at 0.19 EUR (0.30 CAD).

The Microbix Biosystems share (MBX.TO) is listed on 2 stock exchanges, including: Toronto (MBX.TO).

Microbix Biosystems Inc is a Toronto-based biotechnology company that focuses on researching, developing, and marketing diagnostic and therapeutic products. The company operates in three business areas: Diagnostic test systems, infectious diseases, and bioproducts.

The expected revenue of Microbix Biosystems is 18.30 M CAD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Microbix Biosystems is -1.39 M CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Microbix Biosystems is currently -29.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Microbix Biosystems stock.

The price-to-sales ratio (P/S) of Microbix Biosystems is currently 2.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Microbix Biosystems stock.

The Eulerpool Quality Score for Microbix Biosystems is 2/10.

The ISIN of Microbix Biosystems is CA59501P1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Microbix Biosystems is 935162. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Microbix Biosystems is MBX.TO. The ticker symbol is used to trade Microbix Biosystems shares on the stock exchange.

Microbix Biosystems paid dividends every year for the past 0 years.

Microbix Biosystems is assigned to the 'Health' sector.

The dividends of Microbix Biosystems are distributed in CAD.

All fundamentals and in-depth analysis of Microbix Biosystems

Our stock analysis for Microbix Biosystems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Microbix Biosystems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Microbix Biosystems Stock
Microbix Biosystems Revenue→
Microbix Biosystems Stock
Microbix Biosystems Net Income→
Microbix Biosystems Stock
Microbix Biosystems P/E→
Microbix Biosystems Stock
Microbix Biosystems P/S→
Microbix Biosystems Stock
Microbix Biosystems EBIT→
Microbix Biosystems Stock
Microbix Biosystems Dividend→
Microbix Biosystems Stock
Microbix Biosystems Directors Dealings→
Microbix Biosystems Stock
Microbix Biosystems Stocks→
Microbix Biosystems Stock
Microbix Biosystems Market capitalization→
Microbix Biosystems Stock
Microbix Biosystems Debt→
Microbix Biosystems Stock
Microbix Biosystems Liabilities→
Microbix Biosystems Stock
Microbix Biosystems Equity→
Microbix Biosystems Stock
Microbix Biosystems AAQS→
Microbix Biosystems Stock
Microbix Biosystems Employees→
Microbix Biosystems Stock
Microbix Biosystems ROE→
Microbix Biosystems Stock
Microbix Biosystems ROA→
Microbix Biosystems Stock
Microbix Biosystems ROCE→
Microbix Biosystems Stock
Microbix Biosystems News→
Microbix Biosystems Stock
Microbix Biosystems Analyst Price Targets→

Health Stocks

Microbot MedicalMicroBase TechnologyMicron SolutionsMicroba Life SciencesMicroport Cardioflow MedtechMicro-XMicroPort NeuroScientificMicro-Tech Nanjing CoMicropos Medical AB (publ)Micro Digital CoMicroTech Medical (Hangzhou) CoMGI Tech CoAll Stocks A–Z →